Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herentals – page 173

2 092 clinical trials in Herentals, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herentals at a glance
2 092
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 092 trials in Herentals

Open in trial search

Hodgkin's disease

Not recruiting

Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

HIV infection

Not recruiting

Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Abacavir Sulfate
  • Sponsor:Radboud universitair medisch centrum Stichting

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Pfizer Inc.

Study on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Jules Bordet

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Belgian Society Of Medical Oncology

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Huyabio International LLC

Breast cancer

Not recruiting

Study on Amcenestrant Alone and with Drug Combination for Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Study on the Effects of Buspirone Hydrochloride for Patients with Weak or Absent Esophageal Motility

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buspirone Hydrochloride
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herentals

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on follicular lymphoma and diffuse large B-cell lymphoma, evaluating novel therapeutic approaches against traditional treatments.

  • Comparative treatment studies
  • Safety and efficacy evaluation
  • Advanced lymphoma therapies

These trials aim to improve treatment outcomes for patients with various forms of lymphoma through targeted therapies.

02 Multiple Myeloma Research

Groundbreaking studies exploring early intervention in monoclonal gammopathy and smoldering multiple myeloma conditions.

  • Plasma cell disorders
  • Early disease intervention
  • Novel therapeutic approaches

Research focused on preventing progression to active multiple myeloma through innovative treatments.

03 Rheumatology Studies

Investigation of treatment strategies for rheumatoid arthritis, comparing conventional approaches with accelerated biological therapy access.

  • Early RA intervention
  • Long-term effectiveness
  • Treatment optimization

Comprehensive evaluation of various treatment approaches for better disease management outcomes.

04 Gastroenterology Research

Studies examining optimal approaches for PPI deprescription in patients with various gastrointestinal conditions including functional dyspepsia and reflux.

  • Medication optimization
  • Alternative treatment strategies
  • Patient-centered approaches

Focused on developing effective strategies for reducing long-term PPI use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.